Pershing Edward 4

What Happened

• Edward Pershing, CEO and director of Provectus Biopharmaceuticals (PVCT), reported an award/derivative acquisition on 2026-03-12. The Form 4 shows a grant/acquisition of a derivative instrument (no immediate common shares issued; shares listed as N/A, $0.00).
• The instrument is an 8% unsecured convertible promissory note issued under the issuer’s 2025 financing. The note can be converted into Series D‑1 Convertible Preferred Stock at $2.862 per preferred share, and each Series D‑1 preferred is convertible into 10 shares of common stock.

Key Details

• Transaction date: 2026-03-12; Form 4 filed 2026-03-16 (filed within SEC’s two business‑day reporting window).
• Transaction type/code: Award / Derivative (A).
• Shares reported on the Form 4: N/A (derivative award; no common shares issued at reporting).
• Conversion terms (footnotes): the note may be voluntarily converted any time while outstanding and will automatically convert into Series D‑1 preferred 12 months after the note issue date. Series D‑1 preferred converts into 10 common shares each and will automatically convert to common on December 31, 2028 unless converted earlier.
• Note rate: 8% unsecured convertible promissory note (principal plus interest subject to conversion).

Context

• This filing reports a derivative award (a convertible promissory note) rather than an immediate purchase or sale of common stock; therefore there is no immediate change in common‑share ownership reported.
• Convertible instruments can lead to future issuance of preferred and then common shares if converted, per the specific conversion prices and schedules stated above. This report is informational about the instrument granted, not an open‑market buy or sell.